Does Memantine Increase Risk for Falls?
Yes, memantine is associated with an increased risk of falls in patients with dementia, particularly in nursing home settings, though the evidence shows mixed signals depending on the clinical context.
Evidence from Clinical Trials and Guidelines
The 2008 Annals of Internal Medicine guideline review found that falls were among the adverse events reported in comparative trials of cholinesterase inhibitors, with rates "marginally higher" in some treatment groups, though memantine-specific fall data from these pivotal trials showed no statistically significant difference in fall rates compared to placebo 1.
However, the FDA drug label for memantine does not list falls as a specific adverse event in its safety profile, noting instead that high-certainty evidence shows "no difference in falls" when comparing memantine to placebo across combined trial data 2.
Real-World Evidence Shows Increased Fall Risk
Despite the lack of signal in controlled trials, observational studies in nursing home populations consistently demonstrate that memantine increases fall risk:
A 2013 Spanish nursing home study of 4,502 residents found memantine was associated with significantly increased total falls (OR 1.90,95% CI 1.32-2.74), representing nearly double the fall risk compared to non-users 3.
A 2020 Japanese case-control study of 1,832 nursing home residents confirmed memantine as one of multiple medications associated with increased fall risk 4.
A 2013 systematic review and meta-analysis concluded that memantine "increases the risk for falling" among other adverse effects including somnolence, weight gain, confusion, and nervous system disorders 5.
Protective Effect When Discontinuing Cholinesterase Inhibitors
Paradoxically, discontinuing cholinesterase inhibitors when initiating memantine may actually reduce fall risk:
- A 2024 Medicare claims study of 3,612 beneficiaries found that patients who discontinued cholinesterase inhibitors upon memantine initiation had a significantly lower rate of fall-related injury (0.9 vs 2.0 per 100 person-years; HR 0.47,95% CI 0.25-0.88) compared to those who continued both medications 6.
Clinical Implications and Recommendations
For patients with moderate-to-severe Alzheimer's disease, memantine provides established cognitive and functional benefits (3.11 SIB points improvement, 95% CI 2.42-3.92) that must be weighed against fall risk 7.
Risk Mitigation Strategy:
Consider discontinuing cholinesterase inhibitors when initiating memantine to reduce polypharmacy-related fall risk, as this approach does not compromise institutionalization outcomes and reduces fall-related injuries 6.
Exercise particular caution in nursing home residents, where the fall risk appears most pronounced (OR 1.90) 3.
Monitor for additional fall-risk adverse effects including dizziness (6.1% vs 3.9% placebo), somnolence, and confusion, which may contribute to fall risk 7, 5.
Avoid combining memantine with multiple other psychotropic medications, as polypharmacy significantly increases both total falls and injurious falls 3.
Common Pitfalls
The discrepancy between controlled trial data (showing no increased fall risk) and real-world observational studies (showing significant risk) likely reflects differences in patient populations, with nursing home residents being frailer and more vulnerable to medication-related falls than clinical trial participants 4, 3. Do not assume the favorable safety profile from trials applies equally to all clinical settings, particularly institutional care 1, 7.